Company news
Mangoceuticals, Inc. news in 2024
Mangoceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
December 18, 2024
Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split
December 3, 2024
Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
October 30, 2024
MangoRx Announces Formation of Strategy and Alternatives Committee
October 21, 2024
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
October 20, 2024
Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024
October 17, 2024
Mangoceuticals, Inc. announces 1-for 15 reverse stock split as part of NASDAQ compliance plan
October 10, 2024
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
October 2, 2024
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
September 30, 2024
MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
August 14, 2024
MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent
August 12, 2024
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
August 8, 2024
MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market
August 7, 2024
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
July 23, 2024
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
July 17, 2024
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
July 15, 2024
MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department
July 11, 2024
MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets
July 10, 2024
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
June 5, 2024
MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances
June 3, 2024
MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies
June 3, 2024
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
May 27, 2024
MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
May 22, 2024
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
May 20, 2024
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
May 15, 2024
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement
May 1, 2024
Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care
April 24, 2024
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
April 11, 2024
MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment
March 11, 2024
MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth
February 19, 2024
MangoRx awards San Francisco team free MangoRx ED products for one year following big game loss to kansas city
February 12, 2024
MangoRx to offer the Big Game’s losing team a free one year supply of its ED product, mango, to help raise… spirits
February 5, 2024
MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product
February 4, 2024
MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11
January 18, 2024